SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is seeing explosive, meme-like volatility and parabolic price action as retail traders and institutional flows surge ahead of the company's upcoming inclusion in the Nasdaq-100. Community sentiment is deeply polarized, with bulls chasing momentum fueled by AI-driven memory demand and rumors of a stock split, while skeptics warn of an overextended bubble nearing a potential distribution top.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a buyout or aggressive turnaround, fueled by persistent short interest and frustration over the board's delay in naming a permanent CEO. While some market participants see deep value in the brand's international expansion and high dividend yield, others remain skeptical, pointing to lackluster domestic performance and operational challenges.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to its recent award of over $4 million in U.S. government contracts, which investors view as a pivotal validation of its semiconductor and quantum materials technology. The community is actively debating the company's long-term potential to scale its proprietary platform while closely monitoring its ability to move from research-focused government projects to high-volume commercial manufacturing partnerships.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors react to bullish analyst upgrades, a major $151 billion defense contract, and strategic partnerships involving AI-driven network infrastructure and data centers. The community is actively discussing its long-term potential as a key player in the 6G and AI-RAN space, with many comparing its current trajectory to other optical powerhouses while debating the impact of increased institutional buying and recent technical breakouts.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and bullish sentiment driven by investor anticipation of a potential gamma squeeze as market makers move to hedge against heavy call option activity. The community is actively discussing the stock's role in the AI-driven optical interconnect sector, with many highlighting its potential as a critical, high-margin supplier within the broader data center infrastructure space.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility and bearish sentiment as investors weigh concerns over massive AI-related capital expenditures, high debt levels, and recent layoffs against its ambitious cloud infrastructure expansion. While the community is deeply divided between long-term bulls highlighting substantial revenue backlogs and AI-driven growth potential versus skeptics wary of slowing enterprise software demand and valuation risks, the stock continues to face heavy selling pressure.

Maulcoin

Maulcoin is generating significant momentum as a community-driven project that is rallying its 'Mauler' base to push toward milestones like a million-dollar market cap. Participants are actively engaging on social platforms to boost visibility and drive growth, focusing on long-term holding and collective action to establish the token as a durable player in the meme coin space.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a meme-driven cultural asset that traces its roots back to a 2011 BitcoinTalk forum joke, with community members emphasizing its long history and parody status compared to newer meme coins. Investors are actively discussing whale accumulation and a 'billion-dollar' narrative, fueled by community efforts to establish the project as an enduring, ironic alternative to traditional crypto.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest positive late-stage trial results for their pancreatic cancer drug, daraxonrasib, which significantly improved patient survival rates compared to standard chemotherapy. The community is heavily focused on the drug's practice-changing clinical outcomes and the potential for the company to emerge as a dominant force in targeted oncology, fueling intense speculation regarding its long-term market valuation and buyout prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tudor Investment Corp ET AL Raises Stock Position in NovoCure Limited $NVCR

Tudor Investment Corp ET AL boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to its most recent filing with the SEC. The institutional...

JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR

JPMorgan Chase & Co. lifted its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 104.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...

SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR

SG Americas Securities LLC boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 905.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,806 shares of the medical equipment provider...

Novocure to Report First Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast...

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages

Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat reports. One...

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -4.00% and -70.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.</li><li>In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.</li><li>Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, the objective response rate was 34.6%, while the median overall survival was 9.7 months.</li></ul>Novocure (NVCR) shares gained nearly 3% in Thursday’s opening trade after the company announced positive topline results in its metastatic pancreatic cancer therapy trial.Novocure stated that&nbsp;PANOVA-4 met its pre-specified primary endpoint&nbsp;in the Phase 2 trial, achieving a statistically significant improvement in disease control rate. The PANOVA-4 study is a pilot, single-arm study of Tumor Treating Fields (TTFields) concomitant with atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVCR">Novocure</a> trended in the ‘bullish’ territory. NVCR was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Novocure Therapy Improves Disease Control Rate</h2>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.“The positive results from the PANOVA-4 trial further support the potential of Tumor Treating Fields to improve outcomes in pancreatic cancer,” said Uri Weinberg, Chief Medical and Innovation Officer, Novocure.Secondary endpoints in PANOVA-4 included objective response rate (ORR) and overall survival (OS). Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, ORR was 34.6%, while median OS was 9.7 months.Additional secondary endpoints included progression-free survival, one-year survival rate, six-month progression-free survival, duration of response, and incidence of treatment-emergent adverse events.The company stated that TTFields therapy was well-tolerated, and device-related safety was consistent with prior clinical studies.<h2 class="st-heading-2">What Does Novocure Do?</h2>Novocure is a Switzerland-based company that is currently developing and commercializing its Tumor Treating Fields therapy. Its commercialized products have been approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma.<a href="https://stocktwits.com/symbol/NVCR">NVCR stock</a> is down 10% year-to-date and 38% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 22% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, NovoCure Limited logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial

Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.

Equity

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma...

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -28.18% and -66.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR

Tudor Investment Corp ET AL lifted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 606,070 shares of the medical equipment provider's stock after purch...

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.51	--	--	N/A
Q4 '25	-$0.41	-$0.22	46.53%	BEAT
Q3 '25	-$0.42	-$0.33	21.37%	BEAT
Q2 '25	-$0.38	-$0.36	6.27%	BEAT
Q1 '25	-$0.46	-$0.31	33.20%	BEAT

NVCR
NovoCure Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest NVCR News

NVCRNovoCure Ltd